Navigation Links
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Date:6/1/2009

he cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.celltherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective (or increase remission rates or progress free survival) for treatment of relapsed or refractory aggressive NHL as determined by the FDA, the possibility that th
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
3. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
4. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
7. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
10. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
11. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... available in its catalogue: ... for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... Jan. 14, 2014 The Brandeis Medical Center, led by Dr. ... a premier and affordable laser tattoo removal experience with the advanced ... is in providing high quality cosmetic services with cutting edge medical ... " Southern California has seen a dramatic increase ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... REDWOOD CITY, Calif., July 27, 2011 Genomic Health, Inc. (Nasdaq: ... a conference call and webcast on Wednesday, August 3 at 4:30 ...  The call and webcast will follow the release of the second ... Call Details To access the live conference ...
... ROCHESTER, N.Y., July 27, 2011 VirtualScopics, Inc. (NASDAQ: ... imaging for clinical trials, today announced that after the ... release its second quarter 2011 financial results. VirtualScopics, President ... and Financial Officer, Molly Henderson, will host a conference ...
Cached Medicine Technology:Genomic Health to Announce Second Quarter 2011 Financial Results and Host Conference Call on Wednesday, August 3, 2011 2Genomic Health to Announce Second Quarter 2011 Financial Results and Host Conference Call on Wednesday, August 3, 2011 3VirtualScopics Schedules Second Quarter 2011 Earnings Announcement 2
(Date:4/17/2014)... these days to find a colored ribbon representing a disease. ... But what color ribbon does one think of with lung ... for many suffering from the disease, black may be the ... consisting of lung cancer patients, primarily smokers between the ages ... on the stigma often felt by these patients, the emotional ...
(Date:4/17/2014)... 40 years away from a food shortage that will ... a top scientist at the U.S. Agency for International ... production will be limited on a global scale by ... Fred Davies, senior science advisor for the agency,s bureau ... destabilizing by 2050 as energy issues are today.", Davies, ...
(Date:4/17/2014)... after they suffer a cardiac arrest outside of a ... according to new research conducted at St. Michael,s Hospital. ... cardiac arrest get adrenaline, which has been the drug ... Steve Lin, an emergency physician and trauma team leader ... long-term survival rates of patients who suffer a cardiac ...
(Date:4/17/2014)... Researchers from LSTM have called for more research ... coinfection in children in sub-Saharan Africa. In a ... LSTM,s Professor Russell Stothard, working with colleagues in ... Western Reserve University, in Cleveland Ohio, University of ... previous research into the joint burden of HIV/AIDS ...
(Date:4/16/2014)... NJ (April 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: ... 1 study of CDX-1401 in solid tumors, including long-term ... Medicine (Vol 6 Issue 232). The data demonstrate ... clinical benefit in patients with very advanced cancers and ...
Breaking Medicine News(10 mins):Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... SEATTLE, Dec. 3 Targeted Genetics Corporation,(Nasdaq: ... of Health (NIH),Recombinant DNA Advisory Committee,s (RAC) assessment ... in the Phase I/II trial of,tgAAC94 for inflammatory ... subject,s death was a result of,complications from an ...
... national,campaign encouraging Americans to Be Red Cross Ready, the ... for Everyone kit -- an at-home,tool for practicing compression-only ... for Everyone kit is a portable, reasonably priced,practice tool ... in classrooms or,anywhere it is convenient to practice your ...
... Dec. 3 Exelixis,Inc. (Nasdaq: EXEL ) announced today ... conjunction with The American Society of Hematology,48th Annual Meeting from ... The event will be webcast and may be accessed ... Speakers:, -- Michael Morrissey, PhD, President of ...
... Inc.,(Nasdaq: COHR ) today announced that on November ... Directors of The Nasdaq Stock Market ("Nasdaq") to,give Coherent ... periodic reports,for the year ended September 30, 2006 and ... Exchange Commission ("SEC") in order to regain,compliance with Nasdaq,s ...
... N.J., Dec. 3 Covance Inc. (NYSE:,CVD), a ... leading,humanitarian organization, announced today that they are partnering ... for,Orphans and Vulnerable Children in Rwanda. Covance will ... day care centers for,children ages two to four ...
... 3 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... American Society of Hematology (ASH) meeting will be,webcast ... Investors section of the,Company,s website, http://www.millennium.com ., ... presentation will be delivered by Millennium senior management ...
Cached Medicine News:Health News:Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis 2Health News:Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis 3Health News:Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis 4Health News:American Red Cross Offers Compression-Only CPR Practice Kit 2Health News:Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction With The American Society of Hematology 48th Annual Meeting 2Health News:Coherent, Inc. Reports Decision by the Nasdaq Stock Market 2Health News:Coherent, Inc. Reports Decision by the Nasdaq Stock Market 3Health News:Covance and Care Partner on Rwanda Early Childhood Development Initiative 2Health News:Covance and Care Partner on Rwanda Early Childhood Development Initiative 3Health News:Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event 2
... This is an excellent choice to treat ... wrist sprain, or following cast removal. The ... uniform support and compression to the wrist to ... preshaped metal splint prevents painful wrist flexion, and ...
... excellent preventative/thera-peutic device for wearing during ... dampen vibration and shock often transmitted ... Provides relief from painful symptoms of ... easily detachable from the brush lined ...
... options for controlling range of motion of ... better known for its lower extremity bracing ... of patients have benefitted from our custom ... ,Townsends ROM Series post-operative elbow braces come ...
Premium Tennis Elbow Support is 2" wide with loop-lock contact closure and is foam-lined for comfort....
Medicine Products: